Duncan Williams Raises ENDP PT To $51

Duncan Williams has issued a report raising the Price Target on Endo Pharmaceuticals ENDP from $46 to $51 a share. : Duncan Williams writes, “Endo will now have $1 billion in urology sales, providing scale for more efficient manufacturing, procurement, distribution, and pricing negotiation. Additionally the company has gained an international presence in Europe, Australia and Brazil while further diversifying risk away from its dependence on Lidoderm (which now represents 30% of revenues, down from 46%).” ENDP has a Strong Buy Rating and closed at $41.06 yesterday.